Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - Research analysts at HC Wainwright lowered their Q3 2025 earnings estimates for Connect Biopharma in a report released on Wednesday, August 13th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of ($0.24) per share for the quarter, down from their previous forecast of ($0.23). HC Wainwright has a "Buy" rating and a $7.00 price target on the stock. The consensus estimate for Connect Biopharma's current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Connect Biopharma's Q4 2025 earnings at ($0.25) EPS, FY2027 earnings at ($0.89) EPS and FY2029 earnings at ($0.34) EPS.
Separately, Northland Capmk upgraded shares of Connect Biopharma to a "strong-buy" rating in a research note on Tuesday, July 22nd.
Get Our Latest Research Report on CNTB
Connect Biopharma Stock Performance
Shares of NASDAQ CNTB traded down $0.10 during midday trading on Friday, hitting $2.05. The stock had a trading volume of 152,118 shares, compared to its average volume of 216,974. The business's 50 day moving average is $1.52 and its 200-day moving average is $1.05. Connect Biopharma has a 52 week low of $0.51 and a 52 week high of $2.86. The company has a current ratio of 7.24, a quick ratio of 7.24 and a debt-to-equity ratio of 0.01.
Connect Biopharma (NASDAQ:CNTB - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.07.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. XTX Topco Ltd purchased a new position in shares of Connect Biopharma during the second quarter valued at approximately $29,000. Koa Wealth Management LLC purchased a new position in shares of Connect Biopharma during the second quarter valued at approximately $49,000. Finally, AlphaCore Capital LLC purchased a new position in shares of Connect Biopharma during the second quarter valued at approximately $78,000. Institutional investors own 58.72% of the company's stock.
About Connect Biopharma
(
Get Free Report)
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.
Featured Stories
Before you consider Connect Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Connect Biopharma wasn't on the list.
While Connect Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access